Abstract | BACKGROUND: Giant prolactinomas are an unusual subset of macroprolactinomas and are more commonly found in men. The goal of this review is to propose a giant prolactinoma definition and discuss the available therapeutic options for biochemical and tumour volume control. METHODS: A comprehensive search of all published studies was performed between April and November 2012 in electronic databases (PubMed and Ovid). RESULTS: CONCLUSION: There is a scarcity of large studies about the management of giant prolactinoma. Cabergoline is the first-line treatment. However, caution should be exercised when comparing efficacy rates among the different treatment modalities due to the variability in study design and data quality. In this scenario, a 'standard' definition for giant prolactinomas and larger series may be helpful to assess the real efficacy and safety of each therapeutic modality.
|
Authors | Aline B Moraes, Cintia Marques dos Santos Silva, Leonardo Vieira Neto, Mônica R Gadelha |
Journal | Clinical endocrinology
(Clin Endocrinol (Oxf))
Vol. 79
Issue 4
Pg. 447-56
(Oct 2013)
ISSN: 1365-2265 [Electronic] England |
PMID | 23662975
(Publication Type: Journal Article, Review)
|
Copyright | © 2013 John Wiley & Sons Ltd. |
Chemical References |
- Dopamine Agonists
- Ergolines
- Prolactin
- Cabergoline
|
Topics |
- Cabergoline
- Combined Modality Therapy
- Dopamine Agonists
(therapeutic use)
- Ergolines
(therapeutic use)
- Humans
- Pituitary Gland
(drug effects, radiation effects, surgery)
- Pituitary Neoplasms
(blood, pathology, therapy)
- Prolactin
(blood)
- Prolactinoma
(blood, pathology, therapy)
- Treatment Outcome
- Tumor Burden
|